Hologic launches multiplex COVID/flu assay

By LabPulse.com staff writers

October 28, 2021 -- Hologic's Aptima SARS-CoV-2/flu assay is now commercially available in North America and Europe for the simultaneous detection and differentiation of SARS-CoV-2 and influenza A and B.

The three viruses can present with overlapping clinical symptoms, Hologic said. The new assay runs on Hologic's fully automated Panther system, which can provide initial results in approximately three hours and can process more than 1,000 tests in 24 hours, the company said.

The Aptima assay can be used with both anterior nasal swabs and nasopharyngeal sample types. Multiple collection devices can be used, including Hologic's Direct Load Collection Kits, recently launched in the U.S., which are designed to reduce risk of viral transmission and improve laboratory efficiency, the company added.

The multiplex test has the CE Mark for diagnostic use in Europe, is authorized under Interim Order by Health Canada, and has received emergency use authorization from the U.S. Food and Drug Administration.

Hologic launches on-demand molecular testing in Europe
Hologic has launched its Novodiag on-demand molecular test for infectious diseases and antibiotic resistance in Europe.
Hologic posts strong Q3 revenues
Hologic posted strong revenues for its fiscal third quarter. The company attributed the solid financial results in part to recovery from the COVID-19...
Hologic receives CE Mark for CMV detection assay
Hologic has received the CE Mark for its molecular assay to quantify human cytomegalovirus (CMV). The Aptima CMV Quant assay is the company's first test...
Hologic acquires Mobidiag for $795M
Hologic announced it has agreed to acquire Mobidiag, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests...

Copyright © 2021 LabPulse.com

Last Updated bc 11/2/2021 8:42:43 AM